Recombinant interferon alfa 2 a in the treatment of patients with early stage B chronic lymphocytic leukaemia

E. N. McSweeney, F. J. Giles, C. P. Worman, A. P. Jewel, C. P. Tsakona, A. V. Hoffbrand, A. B. Mehta, A. C. Newland, J. C. Cawley, D. Galvani, C. R J Singer, I. R. Grant, D. R. Norfolk, A. H. Goldstone*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Summary. 18 patients with early stage, previously untreated H‐CLL were given interferon alfa (IFNα) 2a, 3 MU thrice weekly, subcutaneously. The peripheral lymphocyte count decreased in all patients. Response was delayed in three patients until they had received a median of 5 months therapy, one of whom had an initial transient increase in lymphocytes. Two patients normalized their blood lymphocyte counts, but neither achieved complete remission (CR). Responses were transient in eight patients lasting a median of 5 months (3–21). Binding anti‐IFNa antibodies were present in 9/17 patients tested (53%). Low titre binding antibodies (< 533 IBU/ml) were not associated with LHR, but high titre antibodies (>4401 IBU/ml) were. Two of 12 patients assessed had a > 3 g/1 increase in baseline serum IgG levels during IFNα therapy, one of whom reverted to pretreatment levels in association with LHR. Haematological toxicity was moderate, other than in two patients, one of whom developed autoimmune haemolytic anaemia and the other thrombo‐cytopenia. We conclude that IFNα lowers the lymphocyte count in early stage CLL, that the response may be delayed and that anti‐IFNcc antibodies may play a role in a proportion of those in whom the response is transient.

Original languageEnglish (US)
Pages (from-to)77-83
Number of pages7
JournalBritish Journal of Haematology
Volume85
Issue number1
DOIs
StatePublished - Sep 1993

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Recombinant interferon alfa 2 a in the treatment of patients with early stage B chronic lymphocytic leukaemia'. Together they form a unique fingerprint.

Cite this